🚀 VC round data is live in beta, check it out!
Sopharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Sopharma and similar public comparables like BioLife Solutions, Paul Hartmann, Shinva, Kestra Medical Technologies and more.
Sopharma Overview
About Sopharma
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products. It generates the majority of its revenue from the Distribution of pharmaceutical products.
Founded
1933
HQ
Employees
5.6K
Website
Sectors
Financials (LTM)
EV
$1B
Sopharma Financials
Sopharma reported last 12-month revenue of $2B and EBITDA of $132M.
In the same LTM period, Sopharma generated $132M in EBITDA and $85M in net income.
Revenue (LTM)
Sopharma P&L
In the most recent fiscal year, Sopharma reported revenue of $2B and EBITDA of $156M.
Sopharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2B | XXX | $2B | XXX | XXX | XXX |
| Gross Profit | — | XXX | $365M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 23% | XXX | XXX | XXX |
| EBITDA | $132M | XXX | $156M | XXX | XXX | XXX |
| EBITDA Margin | 8% | XXX | 10% | XXX | XXX | XXX |
| EBIT Margin | 6% | XXX | 6% | XXX | XXX | XXX |
| Net Profit | $85M | XXX | $83M | XXX | XXX | XXX |
| Net Margin | 5% | XXX | 5% | XXX | XXX | XXX |
| Net Debt | — | — | $254M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Sopharma Stock Performance
Sopharma has current market cap of $1B, and enterprise value of $1B.
Market Cap Evolution
Sopharma's stock price is $2.12.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $1B | 0.3% | XXX | XXX | XXX | $0.16 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSopharma Valuation Multiples
Sopharma trades at 0.9x EV/Revenue multiple, and 11.0x EV/EBITDA.
EV / Revenue (LTM)
Sopharma Financial Valuation Multiples
As of April 8, 2026, Sopharma has market cap of $1B and EV of $1B.
Equity research analysts estimate Sopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sopharma has a P/E ratio of 13.0x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | 0.9x | XXX | 0.9x | XXX | XXX | XXX |
| EV/EBITDA | 11.0x | XXX | 9.4x | XXX | XXX | XXX |
| EV/EBIT | 16.4x | XXX | 16.5x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 4.0x | XXX | XXX | XXX |
| P/E | 13.0x | XXX | 13.3x | XXX | XXX | XXX |
| EV/FCF | — | XXX | (19.4x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Sopharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Sopharma Margins & Growth Rates
Sopharma's revenue in the last 12 month grew by 5%.
Sopharma's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.0M for the same period.
Sopharma's rule of 40 is 13% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sopharma's rule of X is 19% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Sopharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Margin | 8% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Growth | 6% | XXX | (10%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 13% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 19% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 2% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 18% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Sopharma Public Comps
See public comps and valuation multiples for other Medical Supplies comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| BioLife Solutions | XXX | XXX | XXX | XXX | XXX | XXX |
| Paul Hartmann | XXX | XXX | XXX | XXX | XXX | XXX |
| Shinva | XXX | XXX | XXX | XXX | XXX | XXX |
| Kestra Medical Technologies | XXX | XXX | XXX | XXX | XXX | XXX |
| Arjo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sopharma M&A Activity
Sopharma acquired XXX companies to date.
Last acquisition by Sopharma was on XXXXXXXX, XXXXX. Sopharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Sopharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSopharma Investment Activity
Sopharma invested in XXX companies to date.
Sopharma made its latest investment on XXXXXXXX, XXXXX. Sopharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Sopharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Sopharma
| When was Sopharma founded? | Sopharma was founded in 1933. |
| Where is Sopharma headquartered? | Sopharma is headquartered in Bulgaria. |
| How many employees does Sopharma have? | As of today, Sopharma has over 5K employees. |
| Is Sopharma publicly listed? | Yes, Sopharma is a public company listed on Bulgarian Stock Exchange. |
| What is the stock symbol of Sopharma? | Sopharma trades under SFA ticker. |
| When did Sopharma go public? | Sopharma went public in 2000. |
| Who are competitors of Sopharma? | Sopharma main competitors are BioLife Solutions, Paul Hartmann, Shinva, Kestra Medical Technologies. |
| What is the current market cap of Sopharma? | Sopharma's current market cap is $1B. |
| What is the current revenue of Sopharma? | Sopharma's last 12 months revenue is $2B. |
| What is the current revenue growth of Sopharma? | Sopharma revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of Sopharma? | Current revenue multiple of Sopharma is 0.9x. |
| Is Sopharma profitable? | Yes, Sopharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Sopharma? | Sopharma's last 12 months EBITDA is $132M. |
| What is Sopharma's EBITDA margin? | Sopharma's last 12 months EBITDA margin is 8%. |
| What is the current EV/EBITDA multiple of Sopharma? | Current EBITDA multiple of Sopharma is 11.0x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.